November 8, 2019 — This article explores biomarker data trends and challenges, and shares how drug developers, translational scientists, and clinical researchers evaluating biomarkers in early-phase studies can reduce time and cost.
We explore biomarker data trends and challenges, and share how drug developers, translational scientists, and clinical researchers evaluating biomarkers in early-phase studies can:
- Move beyond data overload and leverage cutting-edge technologies to seamlessly transform millions of data points into actionable insights
- Harness advanced informatics and visualization tools to harmonize disparate sources of biomarker data and warehouse them for effective on-study use (e.g., dose selection), as well as downstream use
- Build flexibility, efficiency, and compliance into the rapidly evolving biomarker-informed development process
- Accelerate go/no-go decision-making to reduce time and cost
